期刊文献+

应用焦磷酸测序法检测进展期结直肠癌中K-ras基因点突变 被引量:4

Detection of K-ras mutation in advanced colorectal carcinoma by Pyrosequencing
下载PDF
导出
摘要 目的建立基于焦磷酸测序技术(Pyrosequencing)的结直肠癌K-ras基因点突变的检测方法,并应用于进展期结直肠癌及其转移灶中K-ras基因突变的检测。方法提取116例Ⅳ期结直肠癌及11例转移灶中的DNA,进行PCR扩增后应用Pyrosequencing法检测K-ras基因12及13密码子点突变。结果 116例Ⅳ期结直肠癌中有29例检出K-ras基因点突变,突变率为25.0%,在所有29例突变病例中12密码子点突变率为82.8%(24/29),13密码子点突变率为17.2%(5/29),所有11例转移灶的K-ras基因均与其原发病灶相一致。结论 Pyrosequencing能准确、快速、高通量地进行K-ras基因点突变测定,适合大规模临床标本检测,有利于指导结直肠癌尤其是转移性病变的个体化治疗。 Objective To establish a method for detecting K-ras gene point mutation in colorectal carcinoma ( CRC) based on the pyrosequencing. Methods Genomic DNA was extracted from formalin-fixed,paraffin-embedded CRC tissues,including 127 primary CRC and 20 metastasis lension from CRC. K-ras gene point mutations at codon 12 and codon 13 were analyzed by pyrosequencing. Result K-ras gene point mutations was found in 33 CRC cases,mu-tation rate was 26. 0%. Of all 33 mutation cases,point mutation rate at codon 12 and codon 13 was 81. 8% and 18. 2% respectively. The status of K-ras in metastasis sites were accord with their primary CRC in all 20 cases. Con-clusions Pyrosequeccing is a accurate,rapid and of high throughput means detecting K-ras gene point mutation,it may serve as a practical method for fast batch analysis of clinical samples.
出处 《中国临床保健杂志》 CAS 2010年第4期391-393,I0004,共4页 Chinese Journal of Clinical Healthcare
基金 浙江省自然科学基金资助(Y207427)
关键词 结直肠肿瘤 序列分析 基因 ras 点突变 Colorectal neoplasms Sequence analysis Genes ras Point mutation
  • 相关文献

参考文献13

  • 1Chang SC,Lin JK,Yang SH,et al.Relationship between genetic alterations and prognosis in sporadic colorectal cancer[J].Int J Cancer,2006,118(7):1721-1727.
  • 2Richman SD,Seymour MT,Chambers P,et al.KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan:results from the MRC FOCUS trial[J].J Clin Oncol,2009,27(35):5931-5937.
  • 3Karapetis CS,Khambata-Ford S,Jonker DJ,et al.K-ras mutations and benefit from cetuximab in advanced colorectal cancer[J].N Engl J Med,2008,359(17):1757-1765.
  • 4Bengala C,Bettelli S,Bertolini F,et al.Epidermal growth factor receptor gene copy number,K-ras mutation and pathological response to preoperative cetuximab,5-FU and radiation therapy in locally advanced rectal cancer[J].Ann Oncol,2009,20(3):469-474.
  • 5Jiang Y,Kimchi ET,Staveley-O'Carroll KF,et al.Assessment of K-ras mutation:a step toward personalized medicine for patients with colorectal cancer[J].Cancer,2009,115(16):3609-3617.
  • 6Chen DC,Saarela J,Nuotio I,et al.Comparison of GenFlex Tag array and Pyrosequencing in SNP genotyping[J].J Mol Diagn,2003,5(4):243-249.
  • 7Jordan JA,Butchko AR,Durso MB.Use of pyrosequencing of 16S rRNA fragments to differentiate between bacteria responsible for neonatal sepsis[J].J Mol Diagn,2005,7(1):105-110.
  • 8Brink M,de Goeij AF,Weijenberg MP,et al.K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study[J].Carcinogenesis,2003,24(4):703-710.
  • 9Su YH,Wang M,Brenner DE,et al.Detection of mutated K-ras DNA in urine,plasma,and serum of patients with colorectal carcinoma or adenomatous polyps[J].Ann N Y Acad Sci,2008,1137(1):197-206.
  • 10Tang WY,Elnatan J,Lee YS,et al.c-Ki-ras mutations in colorectal adenocarcinomas from a country with a rapidly changing colorectal cancer incidence[J].Br J Cancer,1999,81(2):237-241.

同被引文献88

  • 1李景南,李潇,钱家鸣,路新卿,杨红.K-ras基因突变通过调节E-cadherin/β-catenin/p120蛋白复合体形成和RhoA蛋白活性对结肠癌细胞株Caco-2转移的影响[J].中国医学科学院学报,2010,32(1):46-50. 被引量:10
  • 2Poehlmann A, Kuester D, Meyer F, et al. K-ras mutation detection in colorectal cancer using the Pyrosequencing technique [J]. PatholResPract,2007,203(7):489 -497.
  • 3Kristensen A T, Wiig J N, Larsen S G, et al. Molecular detection (K-ras) of exfoliated tumour cells in the pelvis is a prognostic factor after resection of rectal cancer [J]. BMC Cancer,2008,27(8) :213-221.
  • 4Onozato W, Yamashita K, Yamashita K, et al. Genetic alterations of K ras may reflect prognosis in stage III colon cancer patients below 60 years of age [J]. J Surg Oncoi,2011, 103(1) :25-33.
  • 5Estrada P, Rojas-Atencio A, Zabala W, et al. Frequency and clinicopathological associations of K ras mutations in Venezuelan patients with colorectal cancer [J]. Invest Clin, 2009,50(1) :55-63.
  • 6Bengala C, Bettelli S, Bertolini F, et al. Epidermal growth factor receptor gene copy number, N ras mutation and pathological response to preoperative cetuximab, 5 FU and radiation therapy in locally advanced rectal cancer[J].Ann Oncol,2009,20(3) :469- 474.
  • 7Jemal A, Thomas A, Murray T, et al. Cancer statistics[J]. CA Cancer J Clin, 2002, 52(1): 23-47.
  • 8Soulieres D, Greer W, Magliocco AM, et al. K-RAS mutation testing in the treatment of metastatic colorec- tal cancer with anti-EGFR therapies [ J ]. Curr Oncol, 2010, 17(1): s31-40.
  • 9Linardou H, Dahabreh I J, Kanaloupiti D, et al. As- sessment of somatic k-ras mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in ad- vanced non-small-cell lung cancer and metastatic colo- rectal cancer[J]. Lancet Oncol, 2005, 9(10): 962- 972.
  • 10Brink M, de Goeij AFPM, Weijenberg MP, et al. K- ras oncogene mutations in sporadic colorectal cancer in the Netherlands cohort study [ J ]. Carcinogenesis, 2003, 24(4) : 703-710.

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部